Search

The article "Clinical Miscellany" presents a selection of ten articles on topics relevant to the clinical practice of the family physician. One of the articles highlights the importance of personal cholesterol level history in relation to cardiovascular disease. Another article analyzes the link between coffee consumption and the occurrence of tachyarrhythmias, concluding that coffee consumption does not increase the risk of arrhythmias, but may decrease it. Furthermore, evidence has been found suggesting that high coffee consumption may decrease the risk of heart failure. On the other hand, it has been shown that raising the head of the bed can reduce symptoms of gastroesophageal reflux. The approval of aducanumab by the FDA does not necessarily mark a new era in Alzheimer's treatment, as Europe has the final say on its effectiveness. Two phase III clinical studies evaluated this monoclonal antibody in patients with cognitive impairment and mild dementia, showing statistically significant improvements in the high-dose group in one study, but not in the other. The decision of the European Medicines Agency will be crucial in determining the future of this treatment. The article also presents two different studies, one on the prevalence of postural hypotension in different healthcare settings and another on the intensive management of cardiovascular risk factors in high-risk individuals with type 2 diabetes and its relationship with cardiovascular autonomic neuropathy. Two other articles review medications that can cause infections as an adverse reaction and best practices regarding the duration of antimicrobial treatment for common infections in primary care. [Extracted from the article]

The article discusses how to create a welcoming environment and facilitating communication with people with a hearing impairment in optometric practice. Topics include important as the prevalence of hearing impairment is increasing in the ageing population; and serves as an introduction to deaf awareness with a particular focus on communication in the optometric practice.

The updated prescribing informationdoes not require dose adjustments for patients who arerentally impaired and removed the requirements forestimated glomerular filtration rate testing before orduring treatment with remdesivir. Nirsevimab-alip (Beyfortus) From: AstraZeneca The FDA has approved nirsevimab-alip (Beyfortus), amonoclonal antibody with activity against respiratorysyncytial virus (RSV) associated with lower respiratorytract disease in neonates and infants born during orentering the first RSV season. Lecanemab-irmb is the first amyloid ß-directed antibodyto be converted from an accelerated approval to atraditional approval for the treatment of AD. [Extracted from the article]

Participants were randomly assigned to receive 1 of 5 doses of lecanemabirmb or a placebo for a 79-week double-blind, placebo-controlled period, followed by a treatment-free gap period of 9 to 59 months (mean, 24 months), followed by an open-label extension period for up to 260 weeks. The pharmacokinetics of lecanemabirmb in patients with hepatic or renal impairment was not evaluated.[1] DOSAGE AND ADMINISTRATION The presence of amyloid p pathology should be confirmed before beginning treatment with lecanemab-irmb. Treatment should be initiated in patients with mild cognitive impairment or who are at the mild dementia stage of disease, which was when treatment began in the clinical trials. [Extracted from the article]

The article discusses pain as a concern among cancer patients. It mentions that 30% of cancer patients experience pain at the time of their diagnosis while 65% to 85% have pain when their disease is at its advanced stage and such pain can be classified into chronic, acute, persistent and breakthrough. It discusses the propensity for cancer patients to experience cognitive impairment.

The article discusses a study on the association between hearing loss and dementia, by Paul Strutt of Macquarie University's Department of Cognitive Science and his colleagues, which was published in the journal "Aging, Neuropsychology and Cognition."

The article reports that the medical journal "Lupus" has published a study which revealed that more patients with systemic lupus erythematosus were influenced by mild cognitive dysfunction in New York City than in Denver, Colorado.

The article reports on a study which found that treatment with growth hormone-releasing hormone was associated with positive cognitive effects among adults with mild cognitive impairment and healthy older adults.

The article discusses research which was reported in the article "The Incidence of MCI Differs by Subtype and Is Higher in Men: The Mayo Clinic Study of Aging" by R. O. Roberts et al. and found that men may be at higher risk than women of mild cognitive impairment (MCI) in old age.

The article presents medical update on Alzheimer's disease (AD). Researchers from the British Geriatric Society examined the effect of antichlolinergic medications on elderly patients with AD. Another research study found an association between eating beaked or broiled fish and reduced risk of developing mild cognitive impairment and AD. Researchers have also discovered a potential biomarker in serum samples that may predict future development of AD.

The article discusses a study conducted by Robert Wilson from Chicago, Illinois-based Rush University Medical Center, about the level of cognition in patients with mild cognitive impairment.